How Will the Market React to Aquestive Therapeutics Inc (AQST) Stock Getting a Bullish Rating

Overall market sentiment has been high on Aquestive Therapeutics Inc (AQST) stock lately. AQST receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator.

Aquestive Therapeutics Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on AQST!

See Full AQST Report

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With AQST Stock Today?

Aquestive Therapeutics Inc (AQST) stock has gained 8.19% while the S&P 500 has fallen -0.18% as of 1:31 PM on Tuesday, Nov 21. AQST has risen $0.15 from the previous closing price of $1.79 on volume of 328,766 shares. Over the past year the S&P 500 is up 14.92% while AQST has risen 113.19%. AQST lost -$0.25 per share in the over the last 12 months. To screen for more stocks like Aquestive Therapeutics Inc click here.

More About Aquestive Therapeutics Inc

Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Sympazan Oral Film, Suboxone Sublingual Film, Exservan Oral Film, and Zuplenz. The product pipeline includes Libervant Buccal Film, AQST-108, and AQST-305. The majority of its revenue comes from the United States. Click Here to get the full Stock Report for Aquestive Therapeutics Inc stock.